Co-Diagnostics (NASDAQ:CODX) and CarePayment Technologies (OTCMKTS:CPYT) Critical Review

Co-Diagnostics (NASDAQ:CODX) and CarePayment Technologies (OTCMKTS:CPYT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.

Analyst Ratings

This is a summary of recent ratings and target prices for Co-Diagnostics and CarePayment Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1	2	1	1	2.40
CarePayment Technologies	0	0	0	0	0.00

Co-Diagnostics presently has a consensus price target of $1.83, indicating a potential upside of 437.00%. Given Co-Diagnostics’ stronger consensus rating and higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than CarePayment Technologies.

Earnings & Valuation

This table compares Co-Diagnostics and CarePayment Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$507,892.00	40.93	-$37.64 million	($0.99)	-0.34
CarePayment Technologies	N/A	N/A	N/A	N/A	N/A

CarePayment Technologies has lower revenue, but higher earnings than Co-Diagnostics.

Institutional & Insider Ownership

15.0% of Co-Diagnostics shares are held by institutional investors. 5.4% of Co-Diagnostics shares are held by company insiders. Comparatively, 13.9% of CarePayment Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Co-Diagnostics and CarePayment Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,347.34%	-70.26%	-61.19%
CarePayment Technologies	N/A	N/A	N/A

Summary

Co-Diagnostics beats CarePayment Technologies on 6 of the 10 factors compared between the two stocks.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

About CarePayment Technologies

CarePayment Technologies, Inc. provides accounts receivable services in the United States. It offers services for accounts receivables generated by healthcare providers in connection with providing healthcare services to their patients under the CarePayment brand name. The company was formerly known as microHelix, Inc. CarePayment Technologies, Inc. was founded in 1991 and is based in Lake Oswego, Oregon.